Lilly, Merck Enter Collaboration Agreement to Research Immuno-Oncology Combination Regimens in Multiple Types of Cancer

Dateline City: KENILWORTH, N.J. & INDIANAPOLIS Combinations of KEYTRUDA® (pembrolizumab) with Alimta® (pemetrexed), Cyramza® (ramucirumab), or necitumumab to be explored KENILWORTH, N.J. & INDIANAPOLIS--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the US and Canada, and Eli Lilly and Company (NYSE:LLY) announced today an oncology clinical trial collaboration to evaluate the safety, tolerability and efficacy of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Lilly compounds in multiple clinical trials: Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orInvestors:Justin Holko, 908-740-1879orLillyEli Lilly and CompanyKeri McGrath, 317-277-3768Communications Managermcgrath_happeks@lilly.com Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: LLY Exchange: NYSE read more
Source: Merck.com - Research and Development News - Category: Pharmaceuticals Tags: Oncology Newsroom Research and Development News Corporate News Latest News Source Type: news